Ainos Advances AI-Powered Healthcare with 'AI Nose' Technology and VELDONA Therapeutics

Ainos Introduces AI Nose Technology

Ainos, Inc. (NASDAQ:AIMD, AIMDW) is making significant strides in the healthcare industry with its innovative AI-powered technologies. The company's flagship product, AI Nose, aims to give artificial intelligence the sense of smell through a breakthrough called Smell ID 1

1

. This technology is poised to revolutionize various sectors, including healthcare, industrial safety, and environmental monitoring.

VELDONA: A Promising Therapeutic Approach

Alongside AI Nose, Ainos is developing VELDONA, a low-dose oral interferon therapy. This treatment shows potential in clinical applications and is protected by global patents 1

1

. The company plans to submit Investigational New Drug (IND) applications to the U.S. FDA for VELDONA's use in treating Sjögren's syndrome and HIV-related oral warts by the second half of 2025 1

1

.

Strategic Goals for 2025

Ainos has outlined ambitious objectives for the coming year:

1. Advancing AI Nose Technology: The company aims to drive mass production and market deployment for smart healthcare, women's health, senior care, and industrial applications. Clinical studies for the second-generation Flora are scheduled to commence in the first half of 2025 1

   1

   .

2. Expanding Strategic Partnerships: Ainos plans to strengthen its collaboration with Mitsubishi Tanabe Pharma and seek new opportunities for AI Nose and VELDONA technologies worldwide 1

   1

   .

3. Enhancing Intellectual Property: The company is committed to securing and developing additional intellectual property to reinforce its technological leadership and long-term value 1

   1

   .

Investor Engagement Initiatives

In a move to increase transparency and shareholder engagement, Ainos has joined the Webull Corporate Connect Service (CCS) platform 2

2

4

4

. This digital platform will allow the company to communicate real-time updates, corporate milestones, and financial results directly to investors 2

2

4

4

.

Company Background

Headquartered in San Diego, California, Ainos is a diversified healthcare company focusing on AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics 1

1

2

2

3

3

4

4

. The company's name is a combination of "AI" and "Nose," reflecting its commitment to empowering individuals with next-generation AI-driven POCT solutions 1

1

2

2

3

3

4

4

.

As Ainos moves into 2025, it aims to accelerate growth and innovation, with a clear focus on improving human health, ensuring environmental sustainability, and enhancing global quality of life through its cutting-edge technologies 1

1

.